Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paul Hartmann AGSTU:PHH2 67 5-Year Yield-on-Cost % is 4.37 as of Aug. 09, 2026, which is 67% above its 10-year median of 2.61. GuruFocus rates STU:PHH2 with a GF Score™ of 67/100 and a GF Value™ of €223.82 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 318 Medical Devices & Instruments companies, Paul Hartmann AG ranks better than 72.33% on this metric.
Paul Hartmann AG's yield on cost for the quarter that ended in Dec. 2025 was 4.37.
The historical rank and industry rank for Paul Hartmann AG's 5-Year Yield-on-Cost % or its related term are showing as below:
STU:PHH2'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.65 Med: 2.61 Max: 4.88
Current: 4.37
During the past 13 years, Paul Hartmann AG's highest Yield on Cost was 4.88. The lowest was 1.65. And the median was 2.61.
STU:PHH2's 5-Year Yield-on-Cost % is ranked better than 72.33% of 318
companies
in the Medical Devices & Instruments industry
Industry Median: 2.355
vs STU:PHH2: 4.37
Paul Hartmann AG (STU:PHH2) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Paul Hartmann AG 5-Year Yield-on-Cost % Related Terms
STU:PHH2 vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Paul Hartmann AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paul Hartmann AG 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paul Hartmann AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Paul Hartmann AG's 5-Year Yield-on-Cost % falls into.
Paul Hartmann AG 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Paul Hartmann AG (STU:PHH2) has a 5-Year Yield-on-Cost % of 4.37 as of Aug. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Paul Hartmann AG and its competitors. This is 67% above median its historical median of 2.61. Over the past decade, Paul Hartmann AG's 5-Year Yield-on-Cost % has ranged from 1.65 to 4.88. According to the industry distribution chart, Paul Hartmann AG ranks #88 out of 318 companies in the Medical Devices & Instruments industry, placing it in the top 27.7%.
Is Paul Hartmann AG's 5-Year Yield-on-Cost % too high?
Paul Hartmann AG's current 5-Year Yield-on-Cost % of 4.37 is 67% above median its 10-year median of 2.61. Over the past 10 years, this metric has ranged from a low of 1.65 to a high of 4.88. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.36. Paul Hartmann AG's value of 4.37 is 85.6% above this industry median. Based on the distribution chart, Paul Hartmann AG ranks #88 out of 318 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Paul Hartmann AG has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paul Hartmann AG's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Paul Hartmann AG ranks #88 out of 318 companies for 5-Year Yield-on-Cost %. This puts Paul Hartmann AG in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. Paul Hartmann AG's value of 4.37 is 85.6% above this benchmark. Historically, Paul Hartmann AG's own 5-Year Yield-on-Cost % has ranged from 1.65 to 4.88 over the past decade. While the company's 10-year median is 2.61 vs. the industry median of 2.36, Paul Hartmann AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.36, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paul Hartmann AG's current 5-Year Yield-on-Cost % of 4.37 is 85.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Paul Hartmann AG and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paul Hartmann AG's current 5-Year Yield-on-Cost % is 4.37, which is 67% above median its own 10-year median of 2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paul Hartmann AG stock overvalued right now?
Based on GuruFocus' analysis, Paul Hartmann AG (STU:PHH2) is currently considered Modestly Undervalued. The stock's GF Value™ is €223.82, compared to a current price of €201.00 — trading 10.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.37, which is 67% above median its 10-year median of 2.61 and 85.6% above the Medical Devices & Instruments industry median of 2.36. Paul Hartmann AG's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Paul Hartmann AG (STU:PHH2), the current 5-Year Yield-on-Cost % is 4.37 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paul Hartmann AG (STU:PHH2) Overvalued in 2026?
Based on GuruFocus' analysis, Paul Hartmann AG stock appears to be undervalued.
The current stock price of €201.00 is trading 10.2% below its estimated GF Value™ of €223.82.
GuruFocus considers Paul Hartmann AG to be Modestly Undervalued.
Key valuation signals for STU:PHH2:
5-Year Yield-on-Cost %: 4.37 (67% above median its 10-year median of 2.61)
GF Value™: €223.82 vs. price of €201.00 (10.2% below fair value)
Industry Position: 85.6% above the Medical Devices & Instruments median (#88 of 318)
No single metric tells the full story. See the STU:PHH2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paul Hartmann AG engages in the production of medical and hygiene products. It operates through Wound Management, Incontinence Management and Infection Management and other segments. The Wound segment comprises wound dressing and treatment, compression therapy, first aid, immobilization, and diagnostics. The Incontinence segment provides incontinence hygiene, patient care, and medical skin care. The Infection segment consists of custom procedure trays, surgical draping systems, disposable surgical instruments, and disinfectants. The Other activities include activities in cotton-wool products, medical consumer goods and pharmaceutical products and others. All the activities are functioned through the region of US and derive revenue through the sale of medical and hygiene products.
67GF Score
Get the complete analysis for STU:PHH2
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PHH2 has been successfully added to your 
